Pfizer and BioNTech to Jointly Develop COVID-19 Vaccine
|
By HospiMedica International staff writers Posted on 11 Apr 2020 |
|
Illustration
Pfizer Inc. (New York, NY, USA) and Biopharmaceutical New Technologies {(BioNTech) Mainz, Germany} have entered into a collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced in March. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage Pfizer’s broad expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.
The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites. BioNTech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance. During the clinical development stage, BioNTech and its partners will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is already covered by BioNTech’s collaboration with Fosun Pharma) upon regulatory approval.
“Combating the COVID-19 pandemic will require unprecedented collaboration across the innovation ecosystem, with companies coming together to unite capabilities like never before,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “I am proud of Pfizer’s collaboration with BioNTech and have every confidence in our ability to harness the power of science – together – to bring forth a potential vaccine that the world needs as quickly as possible.”
“We have already started working with Pfizer on our COVID-19 vaccine and are pleased to announce these further details of our ongoing collaboration, which reflects both companies’ strong commitment to move quickly to bring a safe and efficacious vaccine to patients worldwide,” said Co-Founder and CEO of BioNTech, Ugur Sahin, M.D.
Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies (BioNTech)
The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites. BioNTech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance. During the clinical development stage, BioNTech and its partners will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is already covered by BioNTech’s collaboration with Fosun Pharma) upon regulatory approval.
“Combating the COVID-19 pandemic will require unprecedented collaboration across the innovation ecosystem, with companies coming together to unite capabilities like never before,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “I am proud of Pfizer’s collaboration with BioNTech and have every confidence in our ability to harness the power of science – together – to bring forth a potential vaccine that the world needs as quickly as possible.”
“We have already started working with Pfizer on our COVID-19 vaccine and are pleased to announce these further details of our ongoing collaboration, which reflects both companies’ strong commitment to move quickly to bring a safe and efficacious vaccine to patients worldwide,” said Co-Founder and CEO of BioNTech, Ugur Sahin, M.D.
Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies (BioNTech)
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Enteral Feeding Pump
Instilar 1420
New
Anesthetic Gas Measurement Module
Scio Four
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
AI Model Analyzes Patient Data to Diagnose Multiple Sclerosis With 90% Accuracy
Multiple sclerosis (MS) is a chronic inflammatory condition affecting the central nervous system. Most patients initially experience the relapsing-remitting form (RRMS), characterized by periods of symptom... Read more
Magnetically Navigable Microparticles Enable Targeted Drug Delivery
Abdominal aortic aneurysms (AAA) can be life-threatening if not treated and result in nearly 10,000 deaths annually. Researchers working to improve treatments for AAA could now make it possible for doctors... Read more
AI-Powered Algorithm Automates Analysis of Coronary Stents After Implantation
Every year, over three million people globally receive stents to open blocked blood vessels caused by heart disease. However, monitoring the healing process after stent implantation remains a significant challenge.... Read more
Surgical Techniques
view channel
DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment
One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more
Pioneering Sutureless Coronary Bypass Technology to Eliminate Open-Chest Procedures
In patients with coronary artery disease, certain blood vessels may be narrowed or blocked, requiring a stent or a bypass (also known as diversion) to restore blood flow to the heart. Bypass surgeries... Read more
Intravascular Imaging for Guiding Stent Implantation Ensures Safer Stenting Procedures
Patients diagnosed with coronary artery disease, which is caused by plaque accumulation within the arteries leading to chest pain, shortness of breath, and potential heart attacks, frequently undergo percutaneous... Read more
World's First AI Surgical Guidance Platform Allows Surgeons to Measure Success in Real-Time
Surgeons have always faced challenges in measuring their progress toward surgical goals during procedures. Traditionally, obtaining measurements required stepping out of the sterile environment to perform... Read morePatient Care
view channel
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more
Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more
Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
A groundbreaking innovation enables hospitals to significantly improve instrument processing time and throughput in operating rooms (ORs) and sterile processing departments. Turbett Surgical, Inc.... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read more
Business
view channel
Expanded Collaboration to Transform OR Technology Through AI and Automation
The expansion of an existing collaboration between three leading companies aims to develop artificial intelligence (AI)-driven solutions for smart operating rooms with sophisticated monitoring and automation.... Read more
